Enterprise Value
1.354B
Cash
796.5M
Avg Qtr Burn
N/A
Short % of Float
12.86%
Insider Ownership
28.64%
Institutional Own.
46.48%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bebtelovimab (LY-CoV1404) Details COVID-19 | Approved Update | |
Bamlanivimab (LY-CoV555) Details COVID-19 | Approved Quarterly sales |